Seeking Non-invasive and/or Personalized Delivery Systems for Complex Therapies

The Impulse by Chiesi, the Open Innovation team within the global research-oriented biopharmaceutical group, is launching a call for innovative drug delivery systems to enhance drug targeting and patient outcomes. The company seeks novel solutions to improve therapeutic delivery across three defined areas of critical need.

Approaches of interest

• Oral delivery of biologics - novel formulations, devices, or enabling technologies for peptides, proteins, or complex biotherapeutics that address enzymatic degradation and poor intestinal absorption
• Non-invasive delivery to bypass the blood-brain barrier - intranasal or other non-invasive routes that improve targeting efficiency, bioavailability, and ease of use
• Personalized and customizable delivery systems for ultra-precise dosing - modular, scalable platforms for flexible, on-demand production of personalized dosage forms
• Solutions enabling patient-specific dosing based on age, weight, disease progression, or clinical indicators 

Out of scope:

• Diagnostic approaches, analytical technologies, and oral delivery of small molecules
• Submissions from individual physicians or hospital/private practice workers

Developmental stage of interest: TRL 3-6 are of high interest, with minimum in vitro validation and preference for in vivo data or first-in-human studies.

Please note: Full RFP is attached in the "More Information" section of this page. Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.